Would have like to see this a month ago, how high can it fly? $20(US)?
(Applies to: GNBT)
Generex Common Stock Approved for Listing on Nasdaq Stock Market - Stock
To Begin Trading On Nasdaq National Market on Friday, May 5th -
TORONTO, May 3, 2000 /PRNewswire via COMTEX/ -- Generex Biotechnology
Corporation (OTC Bulletin Board: GNBT) today announced that its common stock has
been approved for listing on the Nasdaq Stock Market. Shares will begin trading
on the Nasdaq National Market at the commencement of trading on Friday, May 5,
2000, under the symbol "GNBT."
Generex is engaged in the research and development of drug delivery systems and
technology. To date, it has focused on developing a platform technology for the
buccal delivery (absorption through the inner cheek walls) of large molecule
drugs which, historically, have been administered only by injection. The first
application for this technology is an insulin formulation (Oralgen(TM) in the
United States and Oralin(TM) in Canada and elsewhere) that is administered as a
fine spray into the oral cavity using Rapidmist(TM), a lightweight hand held
aerosol applicator. Phase II clinical trials of Generex' oral insulin product
presently are underway in the United States, Canada, England and Italy.
Notice: This release and oral statements made from time to time by Company
representatives concerning the same subject matter may contain so-called
"forward-looking statements." These statements can be identified by introductory
words such as "expects," "plans," "will," "estimates," "forecasts," "projects"
or words of similar meaning, and by the fact that they do not relate strictly to
historical or current facts. Forward-looking statements frequently are used in
discussing regulatory submissions and approvals, development programs, etc. Many
factors may cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and uncertainties,
some of which are known and other of which are not. No forward-looking statement
is a guarantee of future results or events, and one should avoid placing undue
reliance on such statements.
SOURCE Generex Biotechnology Corporation
(C) 2000 PR Newswire. All rights reserved.
prnewswire.com
-0-
CONTACT: Paul Gambin of Time Release Corporation, 800-391-6755,
fax - 416-364-8782, info@generex.com; or Jeffrey Volk of Wolfe Axelrod
Weinberger Assoc. LLC, 212-370-4500, fax - 212-370-4505,
jeff@wolfeaxelrod.com, both for Generex
(GNBT) |
